Diamond Biotechnology Co

Diamond Biotechnology Co Quick Ratio

The Quick Ratio (Acid Test) of Diamond Biotechnology Co (6815.TWO) as of Oct 29, 2026 is 0.50. In the previous year, Quick Ratio (Acid Test) was 2.83 — a change of -82.27% (lower).

Quick Ratio

0.50

YoY

-82.27%

Last updated:

Quick Ratio (Acid Test) of Diamond Biotechnology Co is 2025 0.50 . Quick Ratio (Acid Test) of Diamond Biotechnology Co was 2024 2.83 . It decreases by -82.27% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diamond Biotechnology Co Stock analysis

What does Diamond Biotechnology Co do? Diamond Biotechnology Co., Ltd. generates revenue through the research, development, manufacturing, and sale of skincare products and medical equipment. The company's skincare products include facial masks, lotions, creams, and essences, primarily used for facial skin care and cleaning. Medical equipment offerings consist of wires, sonic wave devices, radio wave devices, frozen fat reduction equipment, and micro plastic surgery consumables such as botulinum and collagen injections, targeting skin wrinkle and sagging improvement. The firm also provides medical equipment leasing services and medical beauty management consulting services to its clients. The primary customers for skincare products are individuals seeking facial care solutions, while medical equipment and consumables are purchased by clinics and medical facilities specializing in aesthetic procedures. The company serves both domestic and overseas markets, with its medical beauty management consulting services catering to businesses in the aesthetic industry. Diamond Biotechnology focuses on direct sales of its products and services, leveraging its domestic market presence and expanding into international territories to drive revenue growth. Revenue streams are diversified across product categories and service offerings, with skincare products accounting for a significant portion of sales alongside medical equipment and consumables. The company's medical equipment leasing services provide recurring income, while consulting services support long-term client relationships. By maintaining a dual focus on consumer skincare and professional medical aesthetics, Diamond Biotechnology ensures steady demand across its product lines and service segments. Diamond Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diamond Biotechnology Co stock

Quick Ratio (Acid Test) of Diamond Biotechnology Co is 0.50 in 2025.

Quick Ratio (Acid Test) of Diamond Biotechnology Co changed from 2.83 to 0.50, representing a -82.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Diamond Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Diamond Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Diamond Biotechnology Co

All Key Metrics — Diamond Biotechnology Co